IJBPAS, April, 2025, 14(4): 2309-2324

ISSN: 2277–4998

International Journal of Biology, Pharmacy and Allied Sciences (IJBPAS)

'A Bridge Between Laboratory and Reader'

www.ijbpas.com

OVERCOMING DRUG RESISTANCE IN BREAST CANCER: NOVEL STRATEGIES AND THERAPEUTIC APPROACHES

BATRA K[1], SAHU P[2], SAHU D[1], GUPTA N[1], GUPTA A[1], SHARMA H[1] AND SAHU GK[1*]

1: Rungta Institute of Pharmaceutical Sciences, Bhilai

2: Rungta Institute of Pharmaceutical Sciences & Research, Bhilai

***Corresponding Author: Dr. Gyanesh Kumar Sahu: E Mail:** drgyaneshkumarsahu@gmail.com

Received 20th Dec. 2023; Revised 25th Jan. 2024; Accepted 6th July 2024; Available online 1st April 2025

https://doi.org/10.31032/IJBPAS/2025/14.4.8948

ABSTRACT

Breast cancer remains a significant global health burden, driving ongoing efforts in research and therapeutic development. This review paper explores promising avenues for future research and therapeutic advancement in breast cancer. Immunotherapy emerges as a transformative approach, with immune checkpoint inhibitors and CAR T-cell therapy offering new avenues for enhancing anti-tumor immune responses. Precision medicine initiatives, guided by biomarker-driven therapy selection and targeted therapy expansion, are revolutionizing treatment approaches and improving patient outcomes. Novel drug delivery systems, including nanomedicine-based approaches and liposomal formulations, show promise in optimizing drug delivery and overcoming resistance mechanisms. Modulation of the tumor microenvironment and exploration of combination therapies offer synergistic approaches to enhance treatment efficacy. By leveraging these advancements and fostering collaborative efforts, we can drive progress in breast cancer research, translate scientific discoveries into clinical practice, and ultimately improve outcomes for patients worldwide.

Keywords: Breast Cancer, Novel drug delivery system, Nanotechnology

1. INTRODUCTION:

Overcoming Drug Resistance in Breast cancer remains one of the most prevalent and challenging malignancies globally, affecting millions of individuals each year. While significant progress has been made in the development of therapeutic strategies, drug resistance poses a formidable obstacle to successful treatment outcomes. Overcoming drug resistance is paramount in improving the prognosis and survival rates of patients with breast cancer **[1]**.

1.1. Introduction to Breast Cancer:

Breast cancer is a major concern for women, though it can rarely affect men too. It starts in breast tissue and forms tumors. Age, family history, genes, hormones, and lifestyle can all influence breast cancer risk. While some risks are unchangeable, early detection through mammograms is crucial for successful treatment **[1]**.

Symptoms like lumps, breast changes, or nipple discharge might indicate breast cancer, but a doctor's evaluation is essential for diagnosis. Treatment options depend on the specific cancer and individual factors. It can involve surgery, radiation, medications like hormone therapy or targeted therapy, and even immunotherapy. Often, a team of specialists works together to create a personalized treatment plan for each patient.

The good news is that advancements in research and technology have improved our understanding of breast cancer. Earlier detection and more effective treatments are saving lives. However, challenges like drug resistance and cancer spread (metastasis) remain. Researchers are constantly working on innovative approaches to overcome these hurdles and improve the lives of breast cancer patients **[2]**.

1.2. Mechanisms of Drug Resistance in Breast Cancer

Drug resistance in breast cancer is a multifaceted phenomenon driven by various mechanisms that enable cancer cells to evade the cytotoxic effects of chemotherapy, targeted therapy, and hormonal therapy. Understanding these mechanisms is crucial for developing effective therapeutic strategies to overcome resistance and improve treatment outcomes.



Figure 1.1: Mechanism of drug resistance in breast cancer

Breast cancer cells are like shape-shifting ninjas, constantly evolving ways to evade treatment. One tactic is genetic mutation, where their genes change, making them unrecognizable to drugs designed to target them **[3]**. Imagine a key not fitting a lock anymore.

These cancer cells aren't alone. Their neighborhood, called the tumor microenvironment, is full of helper cells that create a safe haven, protecting them from drugs. Think of it as a fortress shielding the cancer cells.

To make matters worse, some cancer cells can transform into a more aggressive, stem-like form, becoming more invasive and resistant to therapy. Like a chameleon blending into its surroundings, these transformed cells are harder to detect and eliminate.

But cancer cells don't stop there. They can also develop their own "survival skills," activating pathways that help them resist death signals from drugs **[4, 5]**. Picture a soldier with a super-strong shield, deflecting attacks.

Understanding these clever tricks used by cancer cells is key to developing better treatments. By outsmarting these sneaky mechanisms, researchers can design therapies that can finally defeat these formidable foes.

Figure 1.2: Tumor Tissues in Breast lobules

1.3. Targeted Therapies and Resistance Mechanisms in Breast Cancer

Targeted therapies have revolutionized the treatment of breast cancer by specifically targeting molecular pathways involved in tumor growth and progression. However, the development of resistance to targeted therapies poses a significant challenge, limiting their long-term efficacy and clinical benefit. Here, we explore the mechanisms underlying resistance to targeted therapies in breast cancer **[6]**.

Figure 1.3: Targeted therapies in breast cancer

HER2-Targeted Therapies: A Fight Against Overexpression

HER2-positive breast cancer is characterized by an overabundance of the HER2 protein on the cancer cell surface. Drugs like trastuzumab and lapatinib target HER2, blocking its growth signals. But cancer cells can fight back in several ways **[6]**.

- **Amplification on Steroids:** Sometimes, the HER2 gene itself gets amplified, creating even more HER2 protein. This "amplification" makes the cancer cell less susceptible to the drug because there are

simply too many targets for it to bind to effectively **[7]**.

- **Finding a Detour:** Cancer cells may activate alternative signaling pathways, like the PI3K/AKT/mTOR pathway, to bypass the blockade imposed by HER2-targeted therapies. Think of it like a car with a broken steering wheel (HER2) – it can still find ways to move (grow) by using a different control system (alternative pathway) **[8]**.
- **Shape-Shifting Proteins:** Mutations in the HER2 protein itself can change its shape, preventing the drugs from binding properly. Imagine a lock and key – if the key (drug) gets bent, it won't fit the lock (mutated HER2 protein) on the cancer cell anymore **[9]**.

Hormone Therapy: When the Target Changes

Hormone therapy is a mainstay for treating hormone receptor-positive breast cancer, targeting the estrogen receptor (ER) or progesterone receptor (PR) to halt cancer cell growth. However, resistance can develop through various mechanisms **[10]**.

- **Mutated Receptors:** Mutations in the ER gene can alter the part of the receptor that binds to estrogen, making it "stuck on" even without the hormone present. This keeps the cancer cells growing despite the lack of hormonal stimulation.
- **Finding New Allies:** Similar to HER2 resistance, cancer cells can activate alternative signaling pathways to bypass the effects of hormone therapy. These pathways can provide the fuel the cancer cells need to keep growing even when their usual source (estrogen) is blocked.
- **Going Stealth:** In some cases, cancer cells may completely lose their ER or PR altogether. This makes them invisible to hormone therapy drugs, rendering the treatment ineffective.

CDK4/6 Inhibitors: A Chess Game with Cell Cycle Control

CDK4/6 inhibitors, like palbociclib and ribociclib, work by interfering with cell cycle progression in hormone receptor-positive breast cancer. But cancer cells can develop resistance through various strategies **[11]**.

- **Switching Gears:** When CDK4/6 are inhibited, cancer cells may upregulate another protein called CDK2. This CDK2 protein can take over the job of CDK4/6, allowing the cell cycle to continue and promoting resistance.
- **Bypassing the Checkpoint:** The retinoblastoma protein (RB) normally acts as a checkpoint in the cell cycle,

preventing uncontrolled growth. If the RB protein is inactivated, cancer cells can bypass this checkpoint and continue dividing even when CDK4/6 are inhibited.

- **Cellular Reprogramming:** Changes in other cell cycle regulators, like cyclin E or p16, can also contribute to resistance. These alterations can disrupt the normal cell cycle control and allow cancer cells to keep multiplying despite the presence of CDK4/6 inhibitors.

The Fight Continues: Overcoming Resistance and Charting the Future

Understanding these resistance mechanisms is crucial for developing new strategies to combat them. Here are some promising approaches:

- **Combination Therapies:** Combining drugs that target different pathways can help prevent or overcome resistance. Think of it as a double attack – it's harder for the cancer cells to develop resistance to multiple drugs at once **[12]**.
- **Drug Delivery Innovation:** New drug delivery systems can improve the way drugs reach and target cancer cells, potentially overcoming resistance mechanisms **[13]**.
- **Immunotherapy: **Harnessing the body's own immune system to fight cancer cells holds promise for overcoming resistance.
- **Precision Medicine:** Identifying patients most likely to benefit from specific therapies based on their tumor characteristics can optimize treatment strategies and potentially reduce the risk of resistance.



Figure 1.4: Treatment Options for Breast Cancer

1.3. Combination Therapies and Synergistic Approaches in Breast Cancer

Combination therapies have emerged as a promising strategy for overcoming drug resistance and improving treatment outcomes in breast cancer. By targeting multiple pathways simultaneously or exploiting synergistic interactions between different therapeutic agents, combination therapies offer the potential to enhance efficacy and overcome resistance mechanisms. Here, we explore the rationale behind combination therapies and highlight synergistic approaches in breast cancer treatment **[14]**.

1.4.1. Rational Design of Combination Regimens:

Combination therapies are designed to target complementary or overlapping pathways involved in tumor growth and progression. By simultaneously inhibiting multiple signaling pathways or exploiting synthetic lethal interactions, combination regimens aim to maximize therapeutic efficacy and minimize the development of resistance. Rational design of combination regimens involves selecting agents with distinct mechanisms of action and complementary effects to achieve synergistic or additive effects **[15][16]**.

1.4.2. Synergistic Approaches:

Synergistic approaches in breast cancer treatment involve combining different classes of therapeutic agents to exploit synergistic interactions and enhance treatment efficacy. Some synergistic approaches include **[17]**.

- **Chemotherapy and Targeted Therapy:** Combining chemotherapy agents with targeted therapies, such as HER2-targeted therapy or hormone therapy, can enhance cytotoxic effects on cancer cells while minimizing systemic toxicity. Synergistic interactions between chemotherapy and targeted therapy have been demonstrated in various subtypes of breast cancer, leading to improved response rates and survival outcomes **[18]**.
- **Immunotherapy and Targeted Therapy:** Immunotherapy agents, such as immune checkpoint inhibitors, have shown synergistic effects when combined with targeted therapies or chemotherapy in breast cancer. By enhancing anti-tumor immune responses and overcoming immune evasion mechanisms, combination regimens of immunotherapy and targeted therapy hold promise for improving treatment outcomes in breast cancer patients.
- **Dual Targeting of Signaling Pathways:** Dual targeting of signaling pathways involved

in tumor growth and survival can enhance therapeutic efficacy and overcome resistance mechanisms in breast cancer. For example, combining inhibitors of the PI3K/AKT/mTOR pathway with inhibitors of the MAPK pathway or CDK4/6 inhibitors can exert synergistic effects on cancer cell proliferation and survival.

1.4.3. Overcoming Resistance:

Combination therapies offer a strategy for overcoming resistance to single-agent therapies by targeting multiple pathways simultaneously or exploiting synthetic lethal interactions. By disrupting compensatory signaling pathways, preventing the emergence of resistant clones, and enhancing anti-tumor immune responses, combination regimens can overcome resistance mechanisms and improve treatment outcomes in breast cancer.

1.4.4. Clinical Implications:

The development of combination therapies and synergistic approaches holds promise for improving treatment outcomes and prolonging survival in breast cancer patients. Clinical trials evaluating novel combination regimens and biomarker-driven approaches are underway to identify optimal treatment strategies and personalize therapy selection based on individual patient characteristics and tumor biology.

1.4. Novel Drug Delivery Systems for Overcoming Resistance in Breast Cancer

Drug resistance poses a significant challenge in breast cancer treatment, necessitating the development of innovative drug delivery systems to enhance therapeutic efficacy and overcome resistance mechanisms. Novel drug delivery systems offer the potential to improve drug pharmacokinetics, enhance tumor targeting, and minimize off-target toxicity, thereby optimizing treatment outcomes. Here, we explore the role of novel drug delivery systems in overcoming resistance in breast cancer:

1.5.1. Nanomedicine-Based Approaches:

Imagine microscopic carriers loaded with medicine. These are nanoparticles, which can:

- **Target the Enemy:** They can accumulate in tumors, delivering drugs directly to cancer cells and minimizing exposure to healthy tissues **[19, 20]**.
- **Slow and Steady Wins the Race:** Nanoparticles can release drugs slowly over time, overcoming resistance mechanisms that pump drugs out of cells.
- **Combo Power:** They can carry multiple drugs at once, targeting different aspects of cancer and potentially overcoming resistance.

1.5.2. Liposomal Formulations:

Liposomes are like fatty bubbles that can encapsulate drugs. They offer benefits like:

- **Drug Protection:** They shield drugs from breaking down in the body, making them more effective.
- **Targeted Delivery:** They can be decorated with molecules that home in on cancer cells, delivering drugs precisely where they're needed.
- **Reduced Side Effects:** By targeting cancer cells, liposomes can minimize harm to healthy tissues **[21]**.

1.5.3. Polymer-Drug Conjugates for Targeted Delivery:

Attaching drugs to polymers, like plastic chains, creates a powerful duo. These polymer-drug conjugates can:

- **Circulate Longer:** They stay in the bloodstream for extended periods, allowing for more drug to reach the tumor.
- **Targeted Attack:** Similar to liposomes, they can be outfitted with targeting molecules for precise delivery.
- **Controlled Release:** Some release drugs only when they reach the tumor or inside cancer cells, maximizing their impact.

1.5.4. Overcoming Resistance Through Multi-Targeted Approaches:

These innovative drug delivery systems have the potential to overcome resistance and improve treatment outcomes for breast cancer patients. By continuing research and clinical trials, scientists can refine these technologies and bring them closer to routine use in the fight against breast cancer **[22, 23]**.

1.6. Immunotherapy Strategies and Overcoming Resistance in Breast Cancer

Immunotherapy is a powerful tool that harnesses the body's immune system to fight cancer. While it shows promise for breast cancer treatment, some tumors develop resistance, limiting its effectiveness **[24]**.

Immune checkpoint inhibitors, like anti-PD-1 and anti-PD-L1 antibodies, are a type of immunotherapy that helps the immune system recognize and attack cancer cells. These drugs work by blocking signals that normally hold back immune responses. Unfortunately, resistance can occur. Cancer cells can develop new ways to suppress the immune system, or the tumor environment itself can harbor cells that dampen the immune response **[25]**.

Combining immunotherapy with other therapies may be a way to overcome resistance. Chemotherapy, for instance, can make tumors more susceptible to immune attack. Studies have shown that combining chemo and immunotherapy improves survival rates in some breast cancers, especially triple-negative breast cancer (TNBC) **[26]**.

Targeted therapy drugs, like those used for HER2-positive breast cancer, can also work together with immunotherapy to boost the immune response.

Radiotherapy is another potential partner for immunotherapy. Radiotherapy can help the immune system recognize and destroy cancer cells, making it a valuable tool in the fight against breast cancer.

Researchers are working on new strategies to overcome resistance to immunotherapy. Identifying patients most likely to respond to immunotherapy using tests like PD-L1 expression or tumor mutational burden can improve treatment effectiveness. Combining immunotherapy with other treatments may also be a powerful approach, as it allows researchers to target different aspects of cancer and potentially overcome resistance mechanisms. The future of immunotherapy is bright, with new drugs like bispecific antibodies, CAR T-cell therapy, and cancer vaccines being explored.

Further research is needed to find the best combinations of treatments and identify patients who will benefit most from immunotherapy. This will help us unlock the full potential of immunotherapy in the fight against breast cancer.

1.7. Emerging Biomarkers for Predicting and Overcoming Resistance in Breast Cancer

Beating Breast Cancer's Resistance: Biomarkers as Allies **[27]**.

Targeted therapies exist for breast cancer, but cancer cells can become resistant. Biomarkers are emerging tools to help us fight back!

Liquid Biopsies: Spies in the Bloodstream

These minimally invasive tests, like analyzing circulating tumor cells (CTCs) in blood, can track cancer's evolution in real-time. This allows us to detect resistance early and adjust treatment accordingly.

Biomarkers: Tailoring Treatment

Biomarkers can help guide treatment decisions by providing information on:

- **Genetic Checkpoints:** Mutations like HER2 amplification or BRCA mutations can indicate which therapies a patient is likely to respond to **[28]**.
- **Drug Target Levels:** Checking for the presence of drug targets, like estrogen receptors, helps decide if hormone therapy is suitable.
- **Tumor Environment Clues:** Immune system markers can predict how a patient might respond to immunotherapy.

Next-Gen Sequencing: A Deeper Look

Next-generation sequencing (NGS) technologies offer powerful tools to analyze a

tumor's entire genetic makeup, revealing new resistance mechanisms and potential drug targets.

The Future is Personalized

By using these biomarkers, doctors can tailor treatments to each patient's specific cancer, making treatment more effective and reducing resistance. Biomarkers are constantly evolving, offering exciting possibilities for the future of breast cancer treatment.

1.8. Overcoming Resistance in Triple-Negative Breast Cancer (TNBC)

Triple-Negative Breast Cancer (TNBC) is an aggressive form of breast cancer with limited treatment options due to the lack of estrogen, progesterone, and HER2 receptors – targets for common therapies. Overcoming resistance in TNBC is crucial, and researchers are exploring promising new approaches **[29]**.

Unique Challenges of TNBC:

- **Highly Mutated:** TNBC tumors are genetically unstable, constantly changing and making them resistant to treatment.
- **Survival Signal Activation:** These cancers activate pathways that help them survive and resist therapy.
- **Stem Cell Troublemakers:** TNBC may contain stem-like cancer cells that are hard to kill and can contribute to relapse.

New Weapons in the Fight:

- **Immune Checkpoint Blockers:** These drugs help the immune system recognize and attack TNBC cells.
- **PARP Inhibitors:** These drugs target DNA repair weaknesses in some TNBC tumors, especially those with BRCA mutations.
- **DNA Damage Fighters:** These drugs target how cancer cells repair damage, making them more susceptible to chemotherapy and PARP inhibitors.
- **Blocking Blood Vessel Growth:** These drugs cut off the blood supply that tumors need to grow and spread.

The Future of TNBC Treatment

The focus is on developing new therapies and using genetic tests to identify the best treatment for each patient. Combining different therapies and tailoring treatment based on individual tumor characteristics are promising approaches. Continued research is essential to refine these strategies and improve outcomes for TNBC patients.

1.9. Future Directions and Clinical Implications [30, 31]

Breast cancer treatment is constantly evolving, with exciting new directions offering improved outcomes for patients. Here's a glimpse into what the future holds:

Personalized Medicine: Finding the Perfect Match

Imagine treatments tailored to your unique cancer. This is personalized medicine, which uses genetic testing to identify the best therapy for each patient's tumor. By matching patients with the right drugs based on their tumor biology (e.g., genetic mutations), personalized medicine holds promise for improving treatment effectiveness and reducing side effects.

Immunotherapy: Harnessing the Body's Defense System

Immunotherapy helps the body's immune system fight cancer. Future research will explore new immune checkpoint inhibitors, cell therapies, and vaccines. By boosting the immune system and overcoming cancer's defenses, immunotherapy offers the potential for long-term survival.

Targeted Therapies: Sharpshooters Against Cancer

New targeted therapies focus on specific weaknesses in cancer cells. Researchers are developing drugs that target specific mutations, pathways, and immune checkpoints involved in cancer growth and resistance mechanisms. Combining these targeted therapies with other treatments like immunotherapy or chemotherapy may enhance effectiveness and overcome resistance.

Biomarkers: Guiding the Way

Biomarkers are like road signs, helping doctors choose the best treatment. Future research will focus on using advanced tests like liquid biopsies and imaging to identify these signposts and personalize treatment strategies. By understanding a patient's specific cancer makeup through biomarkers, doctors can tailor treatment and improve outcomes.

Patient-Centered Care: Beyond Treatment

Cancer care goes beyond just treating the disease. The future emphasizes patient well-being and survivorship. This includes support services, survivorship programs, and mental health care to address the physical, emotional, and social needs of patients throughout their journey. By providing holistic care, doctors can improve quality of life for both patients and survivors.

The future of breast cancer treatment is bright, with a focus on personalized therapies, harnessing the immune system, and improving patient well-being. These advancements offer a beacon of hope for a future with better outcomes and a higher quality of life for breast cancer patients.

2. CONCLUSION

Despite significant progress in breast cancer treatment, drug resistance remains a formidable challenge. Our review has explored mechanisms of resistance,

innovative therapies, and future directions in breast cancer research. From personalized medicine to immunotherapy, researchers are dedicated to overcoming resistance and improving patient outcomes. Collaboration between scientists, clinicians, and patients drives progress. In conclusion, while drug resistance in breast cancer is daunting, collective efforts offer hope for better treatments and outcomes. Through ongoing research and collaboration, we aim for a future where breast cancer is manageable, not life-threatening.

3. REFERENCES:

[1] Mansoori B, Mohammadi A, Davudian S, Shirjang S, Baradaran B. The different mechanisms of cancer drug resistance: a brief review. Advanced pharmaceutical bulletin. 2017 Sep;7(3):339.

[2] Dalton WS. Mechanisms of drug resistance in breast cancer. InSeminars in Oncology 1990 Aug 1 (Vol. 17, No. 4 Suppl 7, pp. 37-39).

[3] Sheikh A, Hussain SA, Ghori Q, Naeem N, Fazil A, Giri S, Sathian B, Mainali P, Al Tamimi DM. The spectrum of genetic mutations in breast cancer. Asian Pacific Journal of Cancer Prevention. 2015;16(6):2177-85.

[4] M. Sieuwerts A, A. Inda M, Smid M, van Ooijen H, van de Stolpe A, Martens JW, Verhaegh WF. ER and PI3K pathway activity in primary ER positive breast cancer is associated with progression-free survival of metastatic patients under first-line tamoxifen. Cancers. 2020 Mar 27;12(4):802.

[5] Plati J, Bucur O, Khosravi-Far R. Dysregulation of apoptotic signaling in cancer: molecular mechanisms and therapeutic opportunities. Journal of cellular biochemistry. 2008 Jul 1;104(4):1124-49.

[6] Ye F, Dewanjee S, Li Y, Jha NK, Chen ZS, Kumar A, Vishakha, Behl T, Jha SK, Tang H. Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer. Molecular cancer. 2023 Jul 6;22(1):105.

[7] Oh DY, Bang YJ. HER2-targeted therapies—a role beyond breast cancer. Nature reviews Clinical oncology. 2020 Jan;17(1):33-48.

[8] Hanker AB, Sudhan DR, Arteaga CL. Overcoming endocrine resistance in breast cancer. Cancer cell. 2020 Apr 13;37(4):496-513.

[9] Álvarez-Fernández M, Malumbres M. Mechanisms of sensitivity and resistance to CDK4/6 inhibition. Cancer cell. 2020 Apr 13;37(4):514-29.

[10] Scherbakov AM, Krasil'Nikov MA, Kushlinskii NE. Molecular mechanisms of hormone resistance of breast cancer. Bulletin of experimental biology and medicine. 2013 Jul;155:384-95.

[11] Pandey K, An HJ, Kim SK, Lee SA, Kim S, Lim SM, Kim GM, Sohn J, Moon YW. Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review. International journal of cancer. 2019 Sep 1;145(5):1179-88.

[12] Portman N, Alexandrou S, Carson E, Wang S, Lim E, Caldon CE. Overcoming CDK4/6 inhibitor resistance in ER-positive breast cancer. Endocrine-related cancer. 2019 Jan 1;26(1):R15-30.

[13] Papadimitriou MC, Pazaiti A, Iliakopoulos K, Markouli M, Michalaki V, Papadimitriou CA. Resistance to CDK4/6 inhibition: Mechanisms and strategies to overcome a therapeutic problem in the treatment of hormone receptor-positive metastatic breast cancer. Biochimica et BiophysicaActa (BBA)-Molecular Cell Research. 2022 Aug 24:119346.

[14] Núñez C, Capelo JL, Igrejas G, Alfonso A, Botana LM, Lodeiro C. An overview of the effective combination therapies for the treatment of breast cancer. Biomaterials. 2016 Aug 1;97:34-50.

[15] Lee A, Djamgoz MB. Triple negative breast cancer: emerging therapeutic modalities and novel combination therapies. Cancer treatment reviews. 2018 Jan 1;62:110-22.

[16] Correia AS, Gärtner F, Vale N. Drug combination and repurposing for cancer therapy: The example of breast cancer. Heliyon. 2021 Jan 1;7(1).

[17] Lohiya G, Katti DS. A synergistic combination of niclosamide and doxorubicin as an efficacious therapy for all clinical subtypes of breast cancer. Cancers. 2021 Jun 30;13(13):3299.

[18] Ulldemolins A, Seras-Franzoso J, Andrade F, Rafael D, Abasolo I, Gener P, Schwartz Jr S. Perspectives of nano-carrier drug delivery systems to overcome cancer drug resistance

in the clinics. Cancer Drug Resistance. 2021;4(1):44.

[19] Koushik O, Rao Y, Kumar P, Karthikeyan R. Nano drug delivery systems to overcome cancer drug resistance—a review. J NanomedNanotechnol. 2016;7(378):2.

[20] Fang X, Cao J, Shen A. Advances in anti-breast cancer drugs and the application of nano-drug delivery systems in breast cancer therapy. Journal of Drug Delivery Science and Technology. 2020 Jun 1;57:101662.

[21] Ghafari M, Haghiralsadat F, KhanamaniFalahati-pour S, Zavar Reza J. Development of a novel liposomal nanoparticle formulation of cisplatin to breast cancer therapy. Journal of Cellular Biochemistry. 2020 Jul;121(7):3584-92.

[22] Alven S, Nqoro X, Buyana B, Aderibigbe BA. Polymer-drug conjugate, a potential therapeutic to combat breast and lung cancer. Pharmaceutics. 2020 Apr 29;12(5):406.

[23] Kandasamy T, Sen P, Ghosh SS. Multi-targeted drug repurposing approach for breast cancer via integrated functional network analysis. Molecular Informatics. 2022 Aug;41(8):2100300.

[24] Henriques B, Mendes F, Martins D. Immunotherapy in breast cancer: when, how, and what challenges?. Biomedicines. 2021 Nov 14;9(11):1687.

[25] Retecki K, Seweryn M, Graczyk-Jarzynka A, Bajor M. The immune landscape of breast cancer: strategies for overcoming immunotherapy resistance. Cancers. 2021 Nov 29;13(23):6012.

[26] Debien V, De Caluwé A, Wang X, Piccart-Gebhart M, Tuohy VK, Romano E, Buisseret L. Immunotherapy in breast cancer: an overview of current strategies and perspectives. NPJ Breast Cancer. 2023 Feb 13;9(1):7.

[27] Nicolini A, Ferrari P, Duffy MJ. Prognostic and predictive biomarkers in breast cancer: Past, present and future. InSeminars in cancer biology 2018 Oct 1 (Vol. 52, pp. 56-73). Academic Press.

[28] Tarighati E, Keivan H, Mahani H. A review of prognostic and predictive biomarkers in breast cancer. Clinical

and Experimental Medicine. 2023 Feb;23(1):1-6.

[29] Liu Y, Hu Y, Xue J, Li J, Yi J, Bu J, Zhang Z, Qiu P, Gu X. Advances in immunotherapy for triple-negative breast cancer. Molecular cancer. 2023 Sep 2;22(1):145.

[30] Jeibouei S, Akbari ME, Kalbasi A, Aref AR, Ajoudanian M, Rezvani A, Zali H. Personalized medicine in breast cancer: pharmacogenomics approaches. Pharmacogenomics and personalized medicine. 2019 May 27:59-73.

[31] de Ligt KM, de Rooij BH, Hedayati E, Karsten MM, Smaardijk VR, Velting M, Saunders C, Travado L, Cardoso F, Lopez E, Carney N. International development of a patient-centered core outcome set for assessing health-related quality of life in metastatic breast cancer patients. Breast Cancer Research and Treatment. 2023 Apr;198(2):265-81.